Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease

Matthew Bohm, Ronghui Xu, Yiran Zhang, Sashidhar Varma, Monika Fischer, Gursimran Kochhar, Brigid Boland, Siddharth Singh, Robert Hirten, Ryan Ungaro, Eugenia Shmidt, Karen Lasch, Vipul Jairaith, David Hudesman, Shannon Chang, Dana Lukin, Arun Swaminath, Bruce E. Sands, Jean Frederic Colombel, Sunanda KaneEdward V. Loftus, Bo Shen, Corey A. Siegel, William J. Sandborn, Parambir S. Dulai, Siri Kadire, Gloria Tran, Mahmoud Rahal, Satimai Aniwan, Joseph Meserve, Aaron Weiss, Jenna L. Koliani-Pace, James P. Campbell, David Faleck, Adam Winters, Shreya Chablaney

Research output: Contribution to journalArticle

2 Scopus citations


Background: Direct comparisons are lacking between vedolizumab and tumour necrosis factor (TNF)-antagonist therapy in Crohn's disease (CD). Aim: To compare safety and effectiveness of vedolizumab and TNF-antagonist therapy in adult CD patients. Methods: Retrospective observational cohort (May 2014–December 2017) propensity score-weighted comparison of vedolizumab vs TNF-antagonist therapy (infliximab, adalimumab, certolizumab) in CD. Propensity scores were weighted for age, prior treatments, disease complications, extent and severity, steroid dependence, and concomitant immunosuppressive drug use. The primary outcome was comparative risk for infections or non-infectious serious adverse events (requiring antibiotics, antivirals, antifungals, hospitalisation, or treatment discontinuation, or resulting in death). Secondary comparative effectiveness outcomes were clinical remission (resolution of CD-related symptoms), steroid-free clinical remission and endoscopic remission (absence of ulcers/erosions). Results: We included 1266 patients (n = 659 vedolizumab). Rates of non-infectious serious adverse events (odds ratio [OR] 0.072, 95% confidence interval [CI] 0.012-0.242), but not serious infections (OR 1.183, 95% CI 0.786-1.795), were significantly lower with vedolizumab vs TNF-antagonist therapy. Safety comparisons for non-infectious serious adverse events remained significant after adjusting for differences in duration of exposure. No significant difference was observed between vedolizumab and TNF-antagonist therapy for clinical remission (hazard ratio [HR] 0.932, 95% CI 0.707-1.228), steroid-free clinical remission (HR 1.250, 95% CI 0.677-2.310) or endoscopic remission (HR 0.827, 95% CI 0.595-1.151). TNF-antagonist therapy was associated with higher treatment persistence compared with vedolizumab. Conclusions: There was a lower risk of non-infectious serious adverse events, but not serious infections, with vedolizumab vs TNF-antagonist therapy, with no significant difference for achieving disease remission.

Original languageEnglish (US)
JournalAlimentary Pharmacology and Therapeutics
StateAccepted/In press - 2020

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease'. Together they form a unique fingerprint.

  • Cite this

    Bohm, M., Xu, R., Zhang, Y., Varma, S., Fischer, M., Kochhar, G., Boland, B., Singh, S., Hirten, R., Ungaro, R., Shmidt, E., Lasch, K., Jairaith, V., Hudesman, D., Chang, S., Lukin, D., Swaminath, A., Sands, B. E., Colombel, J. F., ... Chablaney, S. (Accepted/In press). Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Alimentary Pharmacology and Therapeutics.